trial

A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia

NCTId NCT05463770
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 15 (actual)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2023-08-22
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
15 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2022-08-30
Primary completion
2023-08-22
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Ulotaront

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor

Sites

8 total
Little Rock, United StatesRogers, United StatesLong Beach, United StatesMontclair, United StatesSan Diego, United StatesHialeah, United StatesNorth Canton, United StatesRichardson, United States

Facts & assertions

4 sourced
Enrollment
15
Phase
PHASE1
Primary Completion Date
2023-08-22
Status
COMPLETED
relationships
The graph out of here
drug
Ulotaront
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication